Decoding Novo Nordisk's Options Activity: What's the Big Picture? - Novo Nordisk (NYSE:NVO)

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 23 unusual trades.

Delving into the details, we found 56% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $401,684, and 14 were calls, valued at $675,514.

Predicted Price Range

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $200.0 for Novo Nordisk over the recent three months.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $70.0 to $200.0 over the preceding 30 days.

Novo Nordisk Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Ask	Bid	Price	Strike Price	Total Trade Price	Open Interest	Volume
NVO	CALL	SWEEP	BULLISH	01/17/25	$2.28	$2.19	$2.25	$125.00	$112.3K	6.6K	702
NVO	PUT	SWEEP	BULLISH	03/21/25	$10.7	$10.65	$10.65	$115.00	$93.7K	1.1K	100
NVO	CALL	TRADE	BULLISH	01/17/25	$13.65	$13.5	$13.6	$100.00	$85.6K	1.1K	78
NVO	PUT	TRADE	BULLISH	03/21/25	$36.25	$35.95	$35.95	$145.00	$71.9K	11	20
NVO	CALL	SWEEP	BULLISH	12/20/24	$2.37	$2.26	$2.37	$120.00	$70.6K	9.7K	632

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Current Position of Novo Nordisk

With a trading volume of 3,829,487, the price of NVO is up by 1.72%, reaching $109.05.
Current RSI values indicate that the stock is may be approaching oversold.
Next earnings report is scheduled for 79 days from now.

What The Experts Say On Novo Nordisk

A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $158.0.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. * An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.

NVONovo Nordisk AS

$46.67-0.87%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.